Press Release
Antigenix Therapeutics Emerges from Stealth with $7 Million Seed Financing to Advance Cancer Treatment for Patients with Aggressive Cancers Who Urgently Need New Treatment Options
PRINCETON NJ, December 17, 2025 — Antigenix Therapeutics, a biotechnology company spearheading the development of novel antibody-drug conjugate (ADC) therapies for cancers resistant to current treatments, today announced $7 million in seed funding. The round was led by Pier70 Ventures, with participation from the New Jersey Economic Development Authority (NJEDA), and a committed group of individual early investors. Antigenix is a spin-out of the venture studio Syridex Bio.
Antigenix Therapeutics is striving to deliver new hope for patients whose cancers have remained highly resistant to treatment. With this funding, the company will begin preparing its pre-clinical program based on a novel target platform to prepare for an Investigational New Drug (IND) submission.
"This moment is about more than the unveiling of our company—it's about furthering our mission to improve the lives of those facing cancer," said Christopher Whitfield, CEO of Antigenix Therapeutics. "Our platform enables us to develop highly targeted therapies for patients facing difficult journeys and uncertain outcomes. We're here to move the field forward, and to give patients and families tangible reasons for hope."
"With our commitment and the support of our talented team and vision-driven investors, we are preparing our first pre-clinical candidates for investigational studies," said Dowdy Jackson, Ph.D., Chief Scientific Officer (CSO). "We are advancing novel antibody-drug conjugates to deliver effective, better treatment options for cancer patients and their oncologists."
The Antigenix leadership team brings over 50 years of life sciences experience, including 25+ drug approvals and launches, along with over 15 years dedicated to advancing ADC technologies. The team has built and grown successful life-science companies and is uniquely positioned to drive innovation in a field where scientific breakthrough translates directly into impact for patients.
Whitfield's career includes more than 25 years in commercial and clinical development roles at industry leaders Lilly, Amgen, and Gilead. Dr. Jackson brings two decades of oncology development experience across MedImmune/AstraZeneca, Agensys/Astellas, Ambrx/J&J, and Innovent Biologics, including foundational contributions to several first-in-class ADC programs.
About Antigenix Therapeutics
Antigenix Therapeutics, a biotech company headquartered in Princeton, NJ, is dedicated to giving cancer patients more hope and more choices. The company is developing antibody-based therapies that precisely target cancer cells to push the boundaries of what is possible in cancer treatment. With deep expertise in antibody-drug conjugate development, translational medicine, and biotech venture creation, Antigenix Therapeutics is advancing a new generation of monoclonal antibody therapies against novel, tumor-specific targets. By harnessing the unique biology of these proteins, the company is working to create safer, more effective treatment options for patients facing the greatest unmet needs.
About the NJEDA
The New Jersey Economic Development Authority (NJEDA) serves as the State's principal agency for driving economic growth. The NJEDA is committed to making New Jersey a national model for inclusive and sustainable economic development by focusing on key strategies to help build strong and dynamic communities, create good jobs for New Jersey residents, and provide pathways to a stronger and fairer economy. Through partnerships with a diverse range of stakeholders, the NJEDA creates and implements initiatives to enhance the economic vitality and quality of life in the State and strengthen New Jersey's long-term economic competitiveness.
About Syridex Bio
Syridex Bio is a life sciences venture studio that transforms breakthrough ideas into purpose-built companies. The firm builds, licenses, or acquires high-potential assets in biopharmaceuticals, diagnostics, medical devices, and digital health, and launches focused ventures designed to advance innovation to patients more rapidly and equitably. Syridex Bio integrates early capital strategy, scientific rigor, and disciplined governance to guide emerging companies through key value-creation milestones.
Antigenix will be supported by Squire Servance, Founder and Managing Partner of Syridex Bio; Veleka Peeples-Dyer, Syridex Bio Partner and Antigenix Board Observer; and Syridex Bio's advisor team of highly experienced industry veterans.
For further information:
E-mail: info@antigenixthera.com